AIM ImmunoTech Files 8-K
Ticker: AIM · Form: 8-K · Filed: Jul 28, 2025 · CIK: 946644
| Field | Detail |
|---|---|
| Company | Aim Immunotech INC. (AIM) |
| Form Type | 8-K |
| Filed Date | Jul 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-update
TL;DR
AIM ImmunoTech filed an 8-K on 7/28/25. Nothing major disclosed yet.
AI Summary
AIM ImmunoTech Inc. filed an 8-K on July 28, 2025, reporting other events and financial statements. The company, formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida, and operates in the biological products sector.
Why It Matters
This filing provides an update on AIM ImmunoTech's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a routine filing with no immediate material financial or operational changes disclosed.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc (company) — Former company name
- July 28, 2025 (date) — Date of report
- Ocala, FL (location) — Principal executive offices
FAQ
What is the primary business of AIM ImmunoTech Inc.?
AIM ImmunoTech Inc. is primarily involved in the biological products sector, specifically biological products excluding diagnostic substances.
When was the report filed?
The report was filed on July 28, 2025.
What was AIM ImmunoTech Inc.'s former name?
AIM ImmunoTech Inc.'s former name was Hemispherx Biopharma Inc.
Where are AIM ImmunoTech Inc.'s principal executive offices located?
AIM ImmunoTech Inc.'s principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.
What type of SEC filing is this?
This is a Form 8-K, which is a current report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 28, 2025 regarding AIM ImmunoTech Inc. (AIM).